Daily Aspirin Intake Slashes Colon Cancer Relapse Risk by 55%
Posted4 months agoActive3 months ago
news.ki.seResearchstory
skepticalmixed
Debate
60/100
Colon CancerAspirinCancer TreatmentMedical Research
Key topics
Colon Cancer
Aspirin
Cancer Treatment
Medical Research
A study found that daily aspirin intake reduces colon cancer relapse risk by 55% in certain patients, but commenters question the presentation of results and potential biases.
Snapshot generated from the HN discussion
Discussion Activity
Moderate engagementFirst comment
19m
Peak period
8
0-6h
Avg / period
2.3
Comment distribution14 data points
Loading chart...
Based on 14 loaded comments
Key moments
- 01Story posted
Sep 19, 2025 at 5:15 AM EDT
4 months ago
Step 01 - 02First comment
Sep 19, 2025 at 5:34 AM EDT
19m after posting
Step 02 - 03Peak activity
8 comments in 0-6h
Hottest window of the conversation
Step 03 - 04Latest activity
Sep 22, 2025 at 2:04 AM EDT
3 months ago
Step 04
Generating AI Summary...
Analyzing up to 500 comments to identify key contributors and discussion patterns
ID: 45299590Type: storyLast synced: 11/20/2025, 4:50:34 PM
Want the full context?
Jump to the original sources
Read the primary article or dive into the live Hacker News thread when you're ready.
This genetic alteration is found in slightly more than 1/3 of patients.
I guess "Anti-inflammatory medication for 3 years after colorectal surgery reduces relapse risk for 55% of 38% of patients" doesn't have the same hopeful ring to it, but I'd prefer honesty.
(plus 38% is not 0.1%)
"So there's that" is not usually slapped on the end of compelling arguments.
Any other reasons to support this style of clickbaity title instead of something intellectually honest that doesn't deflate hope as the reader goes beyond the headline?
Pedantic much? Ever stopped to wonder if there was a point being made, and not a verbatim reference to what a comment said?
The point being 38% is substantial enough for it's 55% to matter. It's not like it just applies to some tiny slice of patients (the proverbial 0.1% - and please don't tell me there's no proverb mentioning 0.1% either).
>Any other reasons to support this style of clickbaity title instead of something intellectually honest that doesn't deflate hope as the reader goes beyond the headline
It does rellapse the risk by 55% (or at least, it would, if the finding replicates and is accurate). It's just that it's the risk for a specific case.
People shouldn't look for hope from headlines to begin with, nor put too much faith on this or that individual announcement. Nor follow something without consulting with a doctor or two.
In this case it's easier for an individual to just try themselves, since it only involves aspirin intake, but in the general case, most such announcements don't go nowhere near of resulting to some new drug, or to being pratictaly applied as part of regular protocols.
Pedantic would be pointing out your spelling error. Now you can call me that again but you'll be correct this time.
> In this case it's easier for an individual to just try themselves, since it only involves aspirin intake
The fact this is your takeaway, even after I used numeric values to explain the overpromise of the headline... wow. Your wild takeaway is exactly why clickbaity, overpromising headlines do real damage.
>The fact this is your takeaway, even after I used numeric values to explain the overpromise of the headline... wow
I covered the overpromise and even explained why it's still a big enough development. This part was making another point that also went wooooosh (about how such findings rarely materialize to treatment, and people shouldn't get their hopes high from headlines to begin with, even IF the finding they write about covers all or most of the cases and not just 55% of 38% of them - and that this is a general rule, even if in this case one can just trivially try the treatment themselves without waiting for a new drug).
I mean, one has to spell it out, and it still IS pedantically misread.
It seems we agree: the hyperbolic, misleading headline wasn't necessary.
I appreciate our interaction as a reminder that even numbers do not clearly communicate information to everyone. This will help me to remember I should exercise caution in what I write to make the point abundantly clear.
I would never want to put end users in situations where they might harm themselves by taking a pill daily based on a poorly worded headline on a tech website. Good luck to you and your new aspirin regimen, though!
People who would do that because of some single paper (most don't replicate anyway), without checking with a doctor, and taking into account general consensus on the matter, are going to do shit like that anyway, this individual headline wont make any difference.
Ah, yes, the excuse that individual actions don't matter in the larger scheme of the world. Dismissing things is convenient when you don't want to think about them anymore.
I guess intellectual dishonesty in links is so common some people don't even care anymore.
Group a: 7.7% with aspirin vs 14.1% recurrence without aspirin.
Group b: 7.7% with aspirin vs 16.8% recurrence without aspirin.
What's nice is that these are real occurrences, not relative risk percentages. They don't need fuzzy numbers to make their results significant.
Of course, there's also the line at the bottom: "Severe adverse events occurred in 16.8% of aspirin recipients and 11.6% of placebo recipients." Ouch. So if you can make it past that increase in severe adverse events you'll be fine.